Search Results - "Seebach, Frank A."

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer by Kelly, William Kevin, Thanigaimani, Pradeep, Sun, Furong, Seebach, Frank A., Lowy, Israel, Sandigursky, Sabina, Miller, Elizabeth

“…TPS5105 Background: Prostate cancer is the leading cause of new cancer diagnoses and the second most common cause of cancer-related death in American men…”
Get full text

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer by Kelly, William Kevin, Hussain, Arif, Saraiya, Biren, Thanigaimani, Pradeep, Sun, Furong, Seebach, Frank A., Lowy, Israel, Sandigursky, Sabina, Miller, Elizabeth

“…TPS284 Background: Prostate cancer is the leading cause of new cancer diagnoses and the second most common cause of cancer-related death in American men…”
Get full text

A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC) by Rowlands, Tracey, Boyapati, Anita, Li, Siyu, Daly, Christopher, Seebach, Frank A., Lowy, Israel, Rietschel, Petra

“…Abstract only TPS9628 Background: Mesenchymal-epithelial transition (MET) factor is a transmembrane tyrosine kinase receptor activated by hepatocyte growth…”
Get full text

Thresholds for cellular disruption and activation of the stress response in renal epithelia by van Why, S K, Kim, S, Geibel, J, Seebach, F A, Kashgarian, M, Siegel, N J

“…Renal ischemia causes a rapid fall in cellular ATP, increased intracellular calcium (Ca(i)), and dissociation of Na(+)-K(+)-ATPase from the cytoskeleton along…”
Get full text

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update by Segal, Neil Howard, Girda, Eugenia, Sohal, Davendra, Lakhani, Nehal J., Olszanski, Anthony J., Fong, Lawrence, Han, Hyunsil, Casey, Kerry A., Li, Siyu, Ganguly, Samit, Seebach, Frank A., Mathias, Melissa Divya, Pelster, Meredith

“…TPS239 Background: REGN7075 is a human costimulatory bispecific antibody designed to bridge epidermal growth factor receptor (EGFR)-expressing tumor cells with…”
Get full text

Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Stein, Mark N., Zhang, Jingsong, Kelly, William Kevin, Wise, David R, Tsao, Kai, Carneiro, Benedito A., Falchook, Gerald Steven, Sun, Furong, Govindraj, Shilpa, Sims, Jennifer S, Zhu, Min, Seebach, Frank A., Lowy, Israel, Thanigaimani, Pradeep, Sandigursky, Sabina, Miller, Elizabeth

“…154 Background: Pts with mCRPC have a poor prognosis with limited treatment options, including minimal response to immunotherapies. REGN5678 is a…”
Get full text

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update by Segal, Neil Howard, Pelster, Meredith, Girda, Eugenia, Fong, Lawrence, Olszanski, Anthony J., Han, Hyunsil, Casey, Kerry A., Li, Siyu, Welf, Erik, Chen, Chieh-I, Skokos, Dimitris, Seebach, Frank A., Lowy, Israel, Fury, Matthew G., Mathias, Melissa Divya, Lakhani, Nehal J.

“…TPS277 Background: There is a need to develop novel immunotherapeutic approaches to enhance responses to immune checkpoint blockade. REGN7075 is a human…”
Get full text

A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer by Zhang, Jingsong, Stein, Mark N., Kelly, William Kevin, Tsao, Che-Kai, Falchook, Gerald Steven, Xu, Yuanfang, Seebach, Frank A., Lowy, Israel, Mohan, Kosalai Kal, Kroog, Glenn, Miller, Elizabeth

“…Abstract only TPS174 Background: Bispecific antibodies (bsAbs) are emerging as a protein-based therapeutic strategy for directing T-cell-mediated cytotoxicity…”
Get full text

A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC by Drilon, Alexander E., Awad, Mark M., Gadgeel, Shirish M., Villaruz, Liza C, Sabari, Joshua K., Perez, Javier, Daly, Christopher, Patel, Shraddha, Li, Siyu, Seebach, Frank A., Lowy, Israel, Magnan, Heather D., Rietschel, Petra

“…TPS8593 Background: MET, also called hepatocyte growth factor receptor (HGFR), is a high-affinity transmembrane protein receptor for HGF. MET is overexpressed…”
Get full text

Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials by Murray, Joseph Christopher, McIntyre, Debra AG, Anagnostou, Valsamo, Brahmer, Julie R., Meisel, Alexander, Sezer, Ahmet, Gogishvili, Miranda, Melkadze, Tamar, Baramidze, Ana, Makharadze, Tamta, He, Adam, Li, Siyu, Jankovic, Vladimir, Seebach, Frank A., Rietschel, Petra, Kim, Young J., Gullo, Giuseppe, Pouliot, Jean-Francois

“…9028 Background: Circulating innate and adaptive immune cells can modulate clinical responses to immune checkpoint inhibition in pts with cancer; however,…”
Get full text

A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer by Drake, Charles G., Zhang, Jingsong, Stein, Mark N., Xu, Yuanfang, Seebach, Frank A., Lowy, Israel, Mohan, Kosalai Kal, Kroog, Glenn, Miller, Elizabeth

“…Abstract only TPS5592 Background: Bispecific antibodies (bsAbs) are emerging as a protein-based therapeutic strategy for directing T-cell-mediated cytotoxicity…”
Get full text

Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis by Ozguroglu, Mustafa, Sezer, Ahmet, Kilickap, Saadettin, Gumus, Mahmut, Bondarenko, Igor, Gogishvili, Miranda, Turk, Haci M., Cicin, Irfan, Bentsion, Dmitry, Gladkov, Oleg, Clingan, Philip R., Sriuranpong, Virote, Rizvi, Naiyer A., McGinniss, Jennifer, Pouliot, Jean-Francois, Lee, Sue, Seebach, Frank A., Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra

“…Abstract only 9085 Background: In the Phase 3, EMPOWER-Lung 1 study, cemiplimab monotherapy provided significant survival benefit and an acceptable safety…”
Get full text

Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma by Sznol, Mario, Lutzky, Jose, Adjei, Alex A., Powell, Steven Francis, He, Aiwu Ruth, Patel, Manish, O'Day, Steven, Pandya, Naimish B., Kaesshaefer, Stephen, Reckner, Monica, Brown, Cheryl, Diaz, Rosa M, Russell, Luke, Peng, Kah Whye, Wiegert, Erol, Gullo, Giuseppe, Seebach, Frank A., Lowy, Israel, Bexon, Alice Susannah

“…Abstract only TPS3161 Background: VV1 is an oncolytic vesicular stomatitis virus engineered to express human IFNβ to enhance cellular anti-tumor immune…”
Get full text

Differential Activation of the STAT Pathway by Angiotensin II via Angiotensin Type 1 and Type 2 Receptors in Cultured Human Fetal Mesangial Cells by Seebach, Frank A., Welte, Thomas, Fu, Xin-Yuan, Block, Lutz-Henning, Kashgarian, Michael

“…The vasoactive peptide angiotensin II is the principal effector of the renin-angiotensin system. It exerts mitogenic and growth-inhibiting effects in many…”
Get full text